New injection attacks tumors from inside

NCT ID NCT06022029

Recruiting now Disease control Sponsor: OncoNano Medicine, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 29 times

Summary

This early-phase trial tests an experimental drug, ONM-501, injected directly into tumors. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and see if combining it with another drug (cemiplimab) helps control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Allegheny Health Network
COMPLETED

Pittsburgh, Pennsylvania, 15224, United States
BRCR Global
WITHDRAWN

Tamarac, Florida, 33321, United States
California Research Institute
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90027, United States
Cancer Care Wollongong
RECRUITING

Wollongong, New South Wales, 2500, Australia

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Gabrail Cancer Center Research
COMPLETED

Canton, Ohio, 44718, United States
MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
Ohio State University
COMPLETED

Columbus, Ohio, 43210, United States
Princess Alexandra Hospital | Metro South Health
RECRUITING

Woolloongabba, Queensland, 4102, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Southern Oncology Clinical Research Unit
COMPLETED

Bedford Park, South Australia, Australia
St John of God Subiaco Hospital
ACTIVE_NOT_RECRUITING

Subiaco, Western Australia, 6008, Australia
St Vincent's Hospital
RECRUITING

Darlinghurst, New South Wales, 2010, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Tasman Oncology Research
RECRUITING

Southport, Queensland, 4215, Australia

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
UPMC Hillman Cancer Center
COMPLETED

Pittsburgh, Pennsylvania, 15232, United States
University of Texas Southwestern Medical Center
COMPLETED

Dallas, Texas, 75390, United States
University of the Sunshine Coast Clinical Trials
RECRUITING

Buderim, Queensland, 4556, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Virginia Cancer Specialists, PC
COMPLETED

Fairfax, Virginia, 22031, United States

Conditions

The condition(s) this trial relates to.

Bites and Stings breast neoplasm cervical carcinoma diffuse large B-cell lymphoma follicular lymphoma head and neck squamous cell carcinoma in situ carcinoma lymphoma lymphoma, non-Hodgkin, familial mantle cell lymphoma melanoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-Hodgkin lymphoma Recurrence skin cancer skin neoplasm Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER CARCINOMA IN SITU CERVIX CANCER DIFFUSE LARGE B CELL LYMPHOMA FOLLICULAR LYMPHOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA LYMPHOMA,NON-HODGKIN MANTLE CELL LYMPHOMA METASTATIC CANCER SKIN CANCER TRIPLE NEGATIVE BREAST CANCER TUMOR RECURRENCE TUMOR, SOLID UVEAL MELANOMA, RECURRENT UVEAL MELANOMA, RECURRENT